data_FAM_000411_REV
#
#  Version 4 -  April 5, 2011  jdw
#
##  Change the item name of the representative flag, added non-standard polymer linkage details,
#   and added nonpolymer residue number assignement pdbx_reference_entity_list.
#
#   Some additional information is needed to properly complete the example as noted.
#
# 
#
_pdbx_reference_entity_family.family_prd_id FAM_000411
_pdbx_reference_entity_family.name          quinoxaline


#
loop_
_pdbx_reference_entity.family_prd_id
_pdbx_reference_entity.prd_id
_pdbx_reference_entity.name
_pdbx_reference_entity.type
_pdbx_reference_entity.class 
_pdbx_reference_entity.formula
_pdbx_reference_entity.formula_weight
FAM_000411 PRD_000001 "TRIOSTIN A" "cyclic octadepsipeptide antibiotic" "antitumor antibiotic"   "C50 H62 N12 O12 S2"  1087.23
FAM_000411 PRD_000002 "[N-MeCys3,N-MeCys7]TANDEM" "quinoxaline-like" "cytotoxic polypeptide antibiotic" ? ?
FAM_000411 PRD_000003 "QUINOMYCIN BISINTERCALATOR" quinoxaline "cytotoxic polypeptide antibiotic" ? ?
FAM_000411 PRD_000004 "Echinomycin" "cytotoxic polypeptide" "quinoxaline antibiotic" "C51 H64 N12 O12 S2" 1101.26
FAM_000411 PRD_000005 "uk63052"     quinomycin "bifunctional intercalating antibiotic" "C56 H68 N10 O14 S2" 1169.32 
#
#
loop_
_pdbx_reference_entity_instances.family_prd_id
_pdbx_reference_entity_instances.prd_id
_pdbx_reference_entity_instances.ordinal
_pdbx_reference_entity_instances.database_name
_pdbx_reference_entity_instances.database_id
_pdbx_reference_entity_instances.details
_pdbx_reference_entity_instances.prd_representative_flag
FAM_000411 PRD_000001  1 PDB 185d ?   Y
FAM_000411 PRD_000001  2 PDB 1vs2 ?   N
FAM_000411 PRD_000001  3 PDB 2da8 ?   N
FAM_000411 PRD_000003  4 PDB 193d "synthetic like Quinomycin HQU SER ALA CYS CPC ???"   N
FAM_000411 PRD_000004  5 PDB 1xvr ?   N
FAM_000411 PRD_000004  6 PDB 1xvk ?   N
FAM_000411 PRD_000004  7 PDB 2adw ?   N
FAM_000411 PRD_000004  8 PDB 1pfe ?   N
FAM_000411 PRD_000004  9 PDB 1xvn ?   N
FAM_000411 PRD_000004 10 PDB 3go3 ?   N
FAM_000411 PRD_000005 11 PDB 193d "QUINOMYCIN PeptideLike HQU S A C CPC"   N


#
loop_
_pdbx_reference_entity_grouping.family_prd_id
_pdbx_reference_entity_grouping.prd_id
_pdbx_reference_entity_grouping.compound_details
FAM_000411 PRD_000001
; TRIOSTIN IS A BICYCLIC OCTADEPSIPEPTIDE, A MEMBER
  OF THE QUINOXALINE CLASS OF ANTIBIOTICS.
  HERE, TRIOSTIN IS REPRESENTED BY GROUPING TOUGHER THE
  SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) QUI
;
FAM_000411 PRD_000003
; QUINOMYCIN IS A BICYCLIC OCTADEPSIPEPTIDE. RESIDUE 1
  IS LINKED TO RESIDUE 8 AND A THIOACETAL BOND BETWEEN
  RESIDUES 3 AND 7.
  THE QUINOXALINE CHROMOPHORE AND THE D-SERINE WERE
  MERGED TO ONE RESIDUE, UDS, SO TO FIT PDB CONVENTION
  OF LINEAR N-TERM TO C-TERM SEQUENCE.
;
FAM_000411 PRD_000004
; THE ECHINOMYCIN IS A BICYCLIC OCTADEPSIPEPTIDE, A MEMBER
  OF THE QUINOXALINE CLASS OF ANTIBIOTICS.
  HERE, ECHINOMYCIN IS REPRESENTED BY GROUPING TOUGHER THE
  SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) QUI.
;
FAM_000411 PRD_000005
; QUINOMYCIN IS A BICYCLIC OCTADEPSIPEPTIDE, A MEMBER                  
 OF THE QUINOXALINE CLASS OF ANTIBIOTICS.                             
 HERE, QUINOMYCIN IS REPRESENTED BY GROUPING TOUGHER THE              
 SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) HQU                      
;


#
loop_
_pdbx_reference_entity_group.family_prd_id
_pdbx_reference_entity_group.prd_id
_pdbx_reference_entity_group.id
_pdbx_reference_entity_group.name
_pdbx_reference_entity_group.description
FAM_000411 PRD_000001 1 "TRIOSTIN"
; TRIOSTIN IS A IS A BICYCLIC OCTADEPSIPEPTIDE.
  BICYCLIZATION IS ACHIEVED BY LINKING THE N- AND
  THE C- TERMINI, AND A DISULPHIDE BOND BETWEEN
  RESIDUES 3 AND 7.
  THE TWO QUINOXALINE CHROMOPHORES ARE LINKED
  TO THE D-SERINE RESIDUES, RESIDUES 1 AND 5.
;
FAM_000411 PRD_000004 1 "ECHINOMYCIN"
; ECHINOMYCIN IS A IS A BICYCLIC OCTADEPSIPEPTIDE.
  BICYCLIZATION IS ACHIEVED BY LINKING THE N- AND
  THE C- TERMINI, AND A THE THIOACETAL BOND BETWEEN
  RESIDUES 3 AND 7.
  THE TWO QUINOXALINE CHROMOPHORES ARE LINKED
  TO THE D-SERINE RESIDUES, RESIDUES 1 AND 5.
;
FAM_000411 PRD_000005 1 "QUINOMYCIN"
; QUINOMYCIN IS A BICYCLIC OCTADEPSIPEPTIDE.            
 BICYCLIZATION IS ACHIEVED BY LINKING THE N- AND       
 THE C- TERMINI, AND A THE THIOACETAL BOND BETWEEN     
 RESIDUES 3 AND 7.                                     
 THE TWO HYDROXYQUINOXALINE CHROMOPHORES ARE LINKED    
 TO THE D-SERINE RESIDUES, RESIDUES 1 AND 5.           
;

#
#  NOTE:  I left this descriptive information here but this could be consolidated
#         elsewhere.  It does not really map precisely to the entity relationships.
#
loop_
_pdbx_reference_entity_group_components.family_prd_id
_pdbx_reference_entity_group_components.prd_id
_pdbx_reference_entity_group_components.group_id
_pdbx_reference_entity_group_components.id
_pdbx_reference_entity_group_components.name
FAM_000411 PRD_000001 1 1 "PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 8"
FAM_000411 PRD_000001 1 2 "QUINALDIC ACID CHROMOPHORE RESIDUES 0 AND 9"
FAM_000411 PRD_000004 1 1 "PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 8"
FAM_000411 PRD_000004 1 2 "QUINOXALINE CHROMOPHORE RESIDUES 0, 9"
FAM_000411 PRD_000005 1 1 "PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 8"
FAM_000411 PRD_000005 1 2 "3-HYDROXYQUINALDIC ACID CHROMOPHORE RESIDUES 0 AND 9"

#
loop_
_pdbx_reference_entity_list.family_prd_id
_pdbx_reference_entity_list.prd_id
_pdbx_reference_entity_list.ref_entity_id
_pdbx_reference_entity_list.type
_pdbx_reference_entity_list.details
_pdbx_reference_entity_list.nonpoly_residue_number
FAM_000411 PRD_000001 1  'polymer'     "PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 8"   .
FAM_000411 PRD_000001 2  'non-polymer' "QUINALDIC ACID CHROMOPHORE"              0
FAM_000411 PRD_000001 3  'non-polymer' "QUINALDIC ACID CHROMOPHORE"              9

FAM_000411 PRD_000004 1  'polymer'     "PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 8"   .
FAM_000411 PRD_000004 2  'non-polymer' "QUINOXALINE CHROMOPHORE"                 0
FAM_000411 PRD_000004 3  'non-polymer' "QUINOXALINE CHROMOPHORE"                 9

FAM_000411 PRD_000005 1  'polymer'     "PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 8"   .
FAM_000411 PRD_000005 2  'non-polymer' "3-HYDROXYQUINALDIC ACID CHROMOPHORE"     0
FAM_000411 PRD_000005 3  'non-polymer' "3-HYDROXYQUINALDIC ACID CHROMOPHORE"     9

##
##  NOTE --  I do not have the remediated PDB files handy so I do not know 
##           the correct residue names PRD_000004 and PRD_0000005 -  I have called 
##           all QUI as in PRD_0000001

loop_
_pdbx_reference_entity_nonpoly.family_prd_id
_pdbx_reference_entity_nonpoly.prd_id
_pdbx_reference_entity_nonpoly.ref_entity_id
_pdbx_reference_entity_nonpoly.name
_pdbx_reference_entity_nonpoly.three_letter_code
FAM_000411 PRD_000001 2 "QUINALDIC ACID CHROMOPHORE" QUI
FAM_000411 PRD_000001 3 "QUINALDIC ACID CHROMOPHORE" QUI

FAM_000411 PRD_000004 2 "QUINOXALINE CHROMOPHORE"    QUI
FAM_000411 PRD_000004 3 "QUINOXALINE CHROMOPHORE"    QUI

FAM_000411 PRD_000005 2 "3-HYDROXYQUINALDIC ACID CHROMOPHORE"  QUI
FAM_000411 PRD_000005 3 "3-HYDROXYQUINALDIC ACID CHROMOPHORE"  QUI


loop_
_pdbx_reference_entity_link.family_prd_id
_pdbx_reference_entity_link.prd_id
_pdbx_reference_entity_link.link_id
_pdbx_reference_entity_link.ref_entity_id_1
_pdbx_reference_entity_link.entity_seq_num_1
_pdbx_reference_entity_link.comp_id_1
_pdbx_reference_entity_link.atom_id_1
_pdbx_reference_entity_link.ref_entity_id_2
_pdbx_reference_entity_link.entity_seq_num_2
_pdbx_reference_entity_link.comp_id_2
_pdbx_reference_entity_link.atom_id_2
_pdbx_reference_entity_link.value_order

FAM_000411 PRD_000001 1 1 1 DSN N  2 . QUI C  'single'
FAM_000411 PRD_000001 2 1 5 DSN N  3 . QUI C  'single'
FAM_000411 PRD_000001 3 1 3 NCY SG 1 7 NCY SG 'single'

FAM_000411 PRD_000004 1 1 1 DSN N  2 . QUI C  'single'
FAM_000411 PRD_000004 2 1 5 DSN N  3 . QUI C  'single'
FAM_000411 PRD_000004 3 1 3 NCY SG 1 7 NCY SG 'single'

FAM_000411 PRD_000005 1 1 1 DSN N  2 . QUI C  'single'
FAM_000411 PRD_000005 2 1 5 DSN N  3 . QUI C  'single'
FAM_000411 PRD_000005 3 1 3 NCY SG 1 7 NCY SG 'single'


#
loop_
_pdbx_reference_entity_poly_nstd_link.family_prd_id
_pdbx_reference_entity_poly_nstd_link.prd_id
_pdbx_reference_entity_poly_nstd_link.ref_entity_id
_pdbx_reference_entity_poly_nstd_link.link_id
_pdbx_reference_entity_poly_nstd_link.entity_seq_num_1
_pdbx_reference_entity_poly_nstd_link.comp_id_1
_pdbx_reference_entity_poly_nstd_link.atom_id_1
_pdbx_reference_entity_poly_nstd_link.entity_seq_num_2
_pdbx_reference_entity_poly_nstd_link.comp_id_2
_pdbx_reference_entity_poly_nstd_link.atom_id_2
_pdbx_reference_entity_poly_nstd_link.value_order
FAM_000411 PRD_000001 1 1 1 DSN C 2 ALA N  'single'
FAM_000411 PRD_000001 1 2 2 ALA C 3 N2C N  'single'
FAM_000411 PRD_000001 1 3 2 ALA C 3 N2C N  'single'
FAM_000411 PRD_000001 1 4 2 ALA C 3 NCY N  'single'
FAM_000411 PRD_000001 1 5 3 N2C C 4 MVA N  'single'
FAM_000411 PRD_000001 1 6 3 NCY C 4 MVA N  'single'
FAM_000411 PRD_000001 1 7 4 MVA C 5 DSN OG 'single'
FAM_000411 PRD_000001 1 8 5 DSN C 6 ALA N  'single'
FAM_000411 PRD_000001 1 8 6 ALA C 7 NCY N  'single'
FAM_000411 PRD_000001 1 9 6 ALA C 7 N2C N  'single'
FAM_000411 PRD_000001 1 8 7 NCY C 8 MVA N  'single'
FAM_000411 PRD_000001 1 9 7 N2C C 8 MVZ N  'single'
## .... abbreviated ---- 


#
loop_
_pdbx_reference_entity_poly.family_prd_id
_pdbx_reference_entity_poly.prd_id
_pdbx_reference_entity_poly.ref_entity_id
_pdbx_reference_entity_poly.type
_pdbx_reference_entity_poly.nstd_chirality
_pdbx_reference_entity_poly.nstd_linkage
_pdbx_reference_entity_poly.nstd_monomer
_pdbx_reference_entity_poly.number_of_monomers
_pdbx_reference_entity_poly.db_code 
_pdbx_reference_entity_poly.db_name 
FAM_000411 PRD_000001 1 "peptide-like" Y Y Y 8 NOR01129 Norine
FAM_000411 PRD_000003 1 "peptide-like" Y Y Y 8 NORXXXXX Norine
FAM_000411 PRD_000004 1 "peptide-like" Y Y Y 8 NOR01126 Norine
FAM_000411 PRD_000005 1 "peptide-like" Y Y Y 8 NORXXXXX Norine

#
loop_
_pdbx_reference_entity_sequence.family_prd_id
_pdbx_reference_entity_sequence.prd_id
_pdbx_reference_entity_sequence.ref_entity_id
_pdbx_reference_entity_sequence.type
_pdbx_reference_entity_sequence.NRP_flag
_pdbx_reference_entity_sequence.one_letter_codes
FAM_000411 PRD_000001  1 "amino acid" Y SACVSACV
FAM_000411 PRD_000003  1 "amino acid" Y SACXSAXX
FAM_000411 PRD_000004  1 "amino acid" Y SACVSACV
FAM_000411 PRD_000005  1 "amino acid" Y SACXSAXX

#
loop_
_pdbx_reference_entity_poly_seq.family_prd_id
_pdbx_reference_entity_poly_seq.prd_id
_pdbx_reference_entity_poly_seq.ref_entity_id
_pdbx_reference_entity_poly_seq.num
_pdbx_reference_entity_poly_seq.modified_mon_id
_pdbx_reference_entity_poly_seq.mon_id   
FAM_000411 PRD_000001 1 1 DSN SER
FAM_000411 PRD_000001 1 2 ALA ALA
FAM_000411 PRD_000001 1 3 NCY CYS
FAM_000411 PRD_000001 1 4 VAL VAL
FAM_000411 PRD_000001 1 5 DSN SER
FAM_000411 PRD_000001 1 6 ALA ALA
FAM_000411 PRD_000001 1 7 NCY CYS
FAM_000411 PRD_000001 1 8 VAL VAL                             
#
FAM_000411 PRD_000003 1 1 UDS SER
FAM_000411 PRD_000003 1 2 ALA ALA
FAM_000411 PRD_000003 1 3 NYB CYS
FAM_000411 PRD_000003 1 4 CPC .
FAM_000411 PRD_000003 1 5 UDS SER
FAM_000411 PRD_000003 1 6 ALA ALA
FAM_000411 PRD_000003 1 7 NCY .
FAM_000411 PRD_000003 1 8 CPC .
#
FAM_000411 PRD_000004 1 1 DSN SER
FAM_000411 PRD_000004 1 2 ALA ALA
FAM_000411 PRD_000004 1 3 N2C CYS
FAM_000411 PRD_000004 1 4 MVA VAL
FAM_000411 PRD_000004 1 5 DSN SER
FAM_000411 PRD_000004 1 6 ALA ALA
FAM_000411 PRD_000004 1 7 NCY CYS
FAM_000411 PRD_000004 1 8 MVA VAL                             
#
FAM_000411 PRD_000005 1 1 DSN SER
FAM_000411 PRD_000005 1 2 ALA ALA
FAM_000411 PRD_000005 1 3 NYB CYS
FAM_000411 PRD_000005 1 4 CPC .
FAM_000411 PRD_000005 1 5 DSN SER
FAM_000411 PRD_000005 1 6 ALA ALA
FAM_000411 PRD_000005 1 7 NCY .
FAM_000411 PRD_000005 1 8 CPC .


#
loop_
_pdbx_reference_entity_related_structures.family_prd_id
_pdbx_reference_entity_related_structures.ordinal
_pdbx_reference_entity_related_structures.citation_id
_pdbx_reference_entity_related_structures.db_name
_pdbx_reference_entity_related_structures.db_accession
_pdbx_reference_entity_related_structures.db_code
_pdbx_reference_entity_related_structures.name
_pdbx_reference_entity_related_structures.formula
FAM_000411 1 2 CCDC 52261 CULVUA 
"Triostin A seqres C5 ALA-CYS-,CYS--VAL,SER- C5 CYS--VAL,SER-ALA-CYS-," "C50 H62 N12 O12 S2"
FAM_000411 2 3 CCDC 148643 CULVUA10
"Triostin A seqres C5 ALA-CYS-,CYS--VAL,SER- C5 CYS--VAL,SER-ALA-CYS-," "C50 H62 N12 O12 S2"
FAM_000411 3 3 CCDC 154901 ZILGOQ
"Triostin C seqres C5 ALA-CYS-,CYS--LEU,SER- C5 CYS--LEU,SER-ALA-CYS-," "C54 H70 N12 O12 S2"
FAM_000411 4 3 CCDC 154902 ZILHAD
"Triostin A seqres C5 ALA-CYS-,CYS--VAL,SER- C5 CYS--VAL,SER-ALA-CYS-," "C50 H63 N12 O12 S2"
FAM_000411 5 4 CCDC  39241 TANDEM30 "Des-N-tetramethyltriostin A" "C46 H54 N12 O12 S2"
FAM_000411 6 4 CCDC   38063 BICKON  "Des-N-tetramethyltriostin A" "C46 H54 N12 O12 S2"
FAM_000411 7 5 CCDC   31779 TANDEM20  "des-N-Tetramethyl-triostin A" "C46 H54 N12 O12 S2"
FAM_000411 8 40 CCDC 154900 ZILGIK 
; Echinomycin bis(quinoline) acetone solvate hydrate
 Echinomycin 2QN, pepseq C5 ALA-CYS-,CYS--VAL,SER- C5 CYS--VAL,SER-ALA-CYS-,
;
 "C53 H66 N10 O12 S2"

#
loop_
_pdbx_reference_entity_src_nat.family_prd_id
_pdbx_reference_entity_src_nat.prd_id
_pdbx_reference_entity_src_nat.ref_entity_id
_pdbx_reference_entity_src_nat.ordinal 
_pdbx_reference_entity_src_nat.taxid
_pdbx_reference_entity_src_nat.organism_scientific 
_pdbx_reference_entity_src_nat.source
_pdbx_reference_entity_src_nat.atcc 
_pdbx_reference_entity_src_nat.db_code 
_pdbx_reference_entity_src_nat.db_name 
FAM_000411 PRD_000001 1 1 45399 "Streptomyces triostinicus" Norine ? NOR01129 Norine
FAM_000411 PRD_000004 1 2 67293 "Streptomyces echinatus."   Norine ? NOR01126 Norine
FAM_000411 PRD_000001 1 3 1931  "Streptomycineae"           "PMID:3271447" ? ? ?
FAM_000411 PRD_000003 1 4 ?     "Streptomyces braegensis, N617-29" "PMID:7853395" ? ? ?
FAM_000411 PRD_000005 1 5 ?     "Streptomyces braegensis japonicus N617-29" NADB ? ? ?

#
loop_
_pdbx_reference_entity_synonyms.family_prd_id
_pdbx_reference_entity_synonyms.prd_id
_pdbx_reference_entity_synonyms.ordinal
_pdbx_reference_entity_synonyms.source
_pdbx_reference_entity_synonyms.name
FAM_000411  PRD_000001   1 PDB "TRIOSTIN"
FAM_000411  PRD_000001   2 SciFinder "Triostin A"
FAM_000411  PRD_000001   3 SciFinder "NSC 244425"
FAM_000411  PRD_000001   4 Merck "Triostins"
FAM_000411  PRD_000001   5 Beilstein "dilactone"
FAM_000411  PRD_000001   6 PubChem "Triostin A"
FAM_000411  PRD_000001   7 PubChem "NSC2444425"
FAM_000411  PRD_000001   8 PubChem "NCI60_001953"
FAM_000411  PRD_000001   9 PubChem "B100928K382"
FAM_000411  PRD_000001   10 ChemSpider "Triostin A"
FAM_000411  PRD_000002   1 PubChem "(N-MeCys(3)-N-MeCys(7))TANDEM"
FAM_000411  PRD_000002   2 PubChem "Cysmetandem (N-MeCys(3)-N-MeCys(7))TANDEM"
FAM_000411  PRD_000002   3 PubChem "N,N-Dimec-tandem (N-MeCys(3)-N-MeCys(7))TANDEM"
FAM_000411  PRD_000002   4 PubChem "(N-Mecys(3),N-mecys(7))tandem"
FAM_000411  PRD_000002   5 PubChem "4-L-Valine-8-L-valine triostin A"
FAM_000411  PRD_000002   6 PubChem "Tandem, N-mecys(3), N-mecys(7)-"
FAM_000411  PRD_000002   7 PubChem "Triostin A, 4-L-valine-8-L-valine-"
FAM_000411  PRD_000002   8 PubChem "(N-Methylcysteinyl(3)-N-methylcysteinyl(7))tandem"
FAM_000411  PRD_000002   9 SciFinder "CysMeTandem"
FAM_000411  PRD_000002   10 PDB "Quinoxaline; (N-MeCys(3)-N-MeCys(7))TANDEM"
FAM_000411  PRD_000002   11 SciFinder "Triostin A, 4-L-valine-8-L-valine"
FAM_000411  PRD_000004   12 PDB "ECHINOMYCIN"
FAM_000411  PRD_000004   13 SciFinder "Antibiotic A 654I"
FAM_000411  PRD_000004   14 Merck "Quinomycin A"
FAM_000411  PRD_000004   15 Beilstein "Quinomycin A"
FAM_000411  PRD_000004   16 Beilstein "Levomycin"
FAM_000411  PRD_000004   17 KEGG "Quinomycin A"
FAM_000411  PRD_000004   18 PubChem "Quinomycin A"
FAM_000411  PRD_000004   19 ChemSpider "Antibiotic C638-8"
FAM_000411  PRD_000004   20 ChemSpider "Crystalline Antibiotic C 638-8"
FAM_000411  PRD_000004   21 ChemSpider "Echinomycin A"
FAM_000411  PRD_000004   22 ChemSpider "Levomycin"
FAM_000411  PRD_000004   23 ChemSpider "Quinomycin A (9CI)"
FAM_000411  PRD_000004   24 ChemSpider "SK 302B"
FAM_000411  PRD_000004   25 ChemBank "echinomycin A"
FAM_000411  PRD_000004   26 ChemBank "levomycin"
FAM_000411  PRD_000004   27 ChemBank "quinomycin A"
FAM_000411  PRD_000004   28 ChemBank "SK 302B"
FAM_000411  PRD_000004   29 ChemBank "S-426-S (lepetit)"
FAM_000411  PRD_000004   30 BioAustralis "Quinomycin A"
FAM_000411  PRD_000004   31 BioAustralis "Actinoleukin"
FAM_000411  PRD_000004   32 BioAustralis "Antibiotic 1491"
FAM_000411  PRD_000004   33 BioAustralis "Antibiotic 59266"
FAM_000411  PRD_000004   34 BioAustralis "Antibiotic X 948"
FAM_000411  PRD_000004   35 BioAustralis "Antibiotic X 53III"
FAM_000411  PRD_000004   36 ChemBank
; 2-Quinoxalinecarboxmide, N,N'-[2,4,12,15,17,25-hexamethyl-11, 
 24-bis(1-methylethyl) -27-(methylthio)-3,6,10,13,16,19,23, 
 26-octaoxo-9,22-dioxa -28-thia-2,5,12,15,18, 
 25-hexaazabicyclo[12.12.3]nonacosan e-7,20-diyl]bis-
;
FAM_000411  PRD_000004   37 ChemBank
; N-[3,11,13,16,24,26-hexamethyl-27-methylsulfanyl-2,5,9,12,15,18,22,
 25-octaoxo-4,17-di(propan-2-yl)-8-(quinoxaline-2-carbonylamino)-6,
 19-dioxa-28-thia-3,10,13,16,23,
 26-hexazabicyclo[12.12.3]nonacosan-21-yl]quinoxaline-2-carboxamide
;
FAM_000411  PRD_000004   38 ChemBank
; N,N'-(2,4,12,15,17,25-hexamethyl-11,24-bis(1-methylethyl)-27-(methylthio)-
 3,6,10,13,16,19,23,26-octaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-
 hexaazabicyclo(12.12.3)nonacosane-7,20-diyl)bis(2-quinoxalinecarboxamide)
;
FAM_000411  PRD_000005   39 PDB "QUINOMYCIN"
FAM_000411  PRD_000005   40 SciFinder "SW 163G"
FAM_000411  PRD_000005   41 SciFinder "Antibiotic UK 63052 (9CI)"
FAM_000411  PRD_000005   42 SciFinder "UK 63052"
FAM_000411  PRD_000005   43 Beilstein "SW-163G"
FAM_000411  PRD_000005   44 PubChem "UK 63052"
FAM_000411  PRD_000005   45 PubChem "Antibiotics UK 63052"
FAM_000411  PRD_000005   46 PubChem "Neuro_000276"
FAM_000411  PRD_000005   47 PubChem "Streptomyces antibiotic"
FAM_000411  PRD_000005   48 PubChem "Streptomyces antibiotic UK-63052"
FAM_000411  PRD_000005   49 PubChem "NSC 630678"
FAM_000411  PRD_000005   50 PubChem "AIDS 073381"
FAM_000411  PRD_000005   51 PubChem "NCI60_009979"
FAM_000411  PRD_000005   52 ChemSpider "Antibiotic UK 63052"
FAM_000411  PRD_000005   53 ChemSpider "Streptomyces antibiotic UK-63052"
FAM_000411  PRD_000005   54 ChembankID Echinomycin
FAM_000411  PRD_000005   55 ChembankID 
; 2-Quinoxalinecarboxmide, N,N'-[2,4,12,15,17,25-hexamethyl-11, 
 24-bis(1-methylethyl) -27-(methylthio)-3,6,10,13,16,19,23, 
 26-octaoxo-9,22-dioxa -28-thia-2,5,12,15,18, 
 25-hexaazabicyclo[12.12.3]nonacosan e-7,20-diyl]bis-
;
FAM_000411  PRD_000005   56 ChembankID "Echinomycin A"
FAM_000411  PRD_000005   57 ChembankID "Levomycin"
FAM_000411  PRD_000005   58 ChembankID "Quinomycin A"
FAM_000411  PRD_000005   59 ChembankID "S-426-S (Lepetit)"
 
#
loop_
_pdbx_reference_entity_annotation.family_prd_id
_pdbx_reference_entity_annotation.prd_id
_pdbx_reference_entity_annotation.ordinal
_pdbx_reference_entity_annotation.source
_pdbx_reference_entity_annotation.type
_pdbx_reference_entity_annotation.text
FAM_000411  PRD_000001   1 NovelAntibiotics Function "Antitumor"
FAM_000411  PRD_000001   2 PubChem Function "antibacterial activity"
FAM_000411  PRD_000004   3 NovelAntibiotics Function "Antitumor"
FAM_000411  PRD_000004   4 PubChem Function "Binds to DNA"
FAM_000411  PRD_000004   5 PubChem Function "inhibitor of RNA synthesis"
 
#
loop_
_pdbx_reference_entity_feature.family_prd_id
_pdbx_reference_entity_feature.prd_id
_pdbx_reference_entity_feature.ordinal
_pdbx_reference_entity_feature.source_ordinal 
_pdbx_reference_entity_feature.source
_pdbx_reference_entity_feature.type
_pdbx_reference_entity_feature.value
FAM_000411  PRD_000001   1 1 CAS External_Reference_ID "13758-27-5"
FAM_000411  PRD_000001   2 1 Merck External_Reference_ID "14:9733"
FAM_000411  PRD_000001   3 1 Beilstein External_Reference_ID "604469"
FAM_000411  PRD_000001   4 1 NovelAntibiotics External_Reference_ID "140098"
FAM_000411  PRD_000001   5 1 PubChem External_Reference_ID "316447"
FAM_000411  PRD_000001   6 1 ChemSpider External_Reference_ID "65433"
FAM_000411  PRD_000001   7 1 KEGG KEGG_CompoundID "C15721"
FAM_000411  PRD_000001   8 1 MESH MESH_Unique_ID "C031945"
FAM_000411  PRD_000001   9 1 ChemSpider SMILE
;
O=C3N(C)[C@H](C(=O)OC[C@@H](NC(=O)c1nc2c(nc1)cccc2)C(=O)N[C@H](C(=O)N(C)[C@H]4C(=O)N(C)[C@H](C(=O)OC[C@H](C(=O)N[C@H](C(=O)N([C@@H]3CSSC4)C)C)NC(=O)c5nc6c(nc5)cccc6)C(C)C)C)C(C)C
;
FAM_000411  PRD_000001   10 1 WikiPedia Image 
 http://upload.wikimedia.org/wikipedia/commons/thumb/6/63/Triostin_A.png/800px-Triostin_A.png
FAM_000411  PRD_000001   11 1 Nature Image_biosynthesis 
 http://www.nature.com/nchembio/journal/v2/n8/images/nchembio803-sc1.jpg
FAM_000411 PRD_000002 12 1 PubChem External_Reference_ID 3806514 
FAM_000411 PRD_000002 13 1 CAS External_Reference_ID "102390-05-6"
FAM_000411 PRD_000002 14 1 MESH MESH_Unique_ID "C075619"
FAM_000411 PRD_000003 15 1 ACS Image
  http://pubs.acs.org/appl/literatum/publisher/achs/journals/production/bichaw/2008/bichaw.2008.47.issue-30/bi800573p/images/medium/bi-2008-00573p_0001.gif
FAM_000411  PRD_000004   16 1 CAS External_Reference_ID "512-64-1"
FAM_000411  PRD_000004   17 1 Merck External_Reference_ID "14:3497"
FAM_000411  PRD_000004   18 1 Beilstein External_Reference_ID "1071158"
FAM_000411  PRD_000004   19 2 Beilstein External_Reference_ID "78671"
FAM_000411  PRD_000004   20 1 NovelAntibiotics External_Reference_ID "140094"
FAM_000411  PRD_000004   21 1 PubChem External_Reference_ID "23724556"
FAM_000411  PRD_000004   22 2 PubChem External_Reference_ID "24868284"
FAM_000411  PRD_000004   23 1 ChemSpider External_Reference_ID "3085"
FAM_000411  PRD_000004   24 1 ChemDB External_Reference_ID "3966488"
FAM_000411  PRD_000004   25 1 ChemBank External_Reference_ID "907311"
FAM_000411  PRD_000004   26 1 KEGG KEGG_CompoundID "C15722"
FAM_000411  PRD_000004   27 1 MESH MESH_Unique_ID "D004448"
FAM_000411  PRD_000004   28 1 ChemBank SMILE
;
CSC1SCC2N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C(=O)C1N(C)C(=O)C(C)NC(=O)C(COC(=O)C(C(C)C)N(C)C2=O)NC(=O)c3cnc4ccccc4n3)NC(=O)c5cnc6ccccc6n5
;
FAM_000411  PRD_000004   29 1 Sigma-Aldrich Vender_ID E-4392
FAM_000411  PRD_000004   30 1 "BioAustralis Fine Chemicals" URL http://www.bioaustralis.com/pdfs/quinomycina.pdf
FAM_000411  PRD_000004   31 1 Axxora Image http://www.axxora.com/files/formula/380-201_new.gif
FAM_000411  PRD_000004   32 1 Cancer.gov URL http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=39587
FAM_000411  PRD_000004   33 1 Sigma-Aldrich URL http://www.sigmaaldrich.com/catalog/search/ProductDetail/FLUKA/44659
FAM_000411  PRD_000004   34 1 Alexis-Biochemicals URL http://www.alexis-biochemicals.com/Echinomycin.5+M58cde746e0d.0.html
FAM_000411  PRD_000004   35 1 PubChem InChI
;
InChI=1/C51H64N12O12S2/c1-25(2)38-49(72)74-22-36(59-42(65)34-21-53-30-
17-13-15-19-32(30)57-34)44(67)55-28(6)46(69)63(10)40-48(71)62(9)39(26(3)
4)50(73)75-23-35(58-41(64)33-20-52-29-16-12-14-18-31(29)56-33)43(66)54-
27(5)45(68)60(7)37(47(70)61(38)8)24-77-51(40)76-11/h12-21,25-28,35-40,
51H,22-24H2,1-11H3,(H,54,66)(H,55,67)(H,58,64)(H,59,65)/f/h54-55,58-59H 
;
FAM_000411  PRD_000005   36 1 CAS External_Reference_ID "120763-23-7"
FAM_000411  PRD_000005   37 2 CAS External_Reference_ID "120832-02-2"
FAM_000411  PRD_000005   38 1 Beilstein External_Reference_ID "11250492"
FAM_000411  PRD_000005   39 1 PubChem External_Reference_ID "149070"
FAM_000411  PRD_000005   40 1 ChemSpider External_Reference_ID "131388"
FAM_000411  PRD_000005   41 1 MESH MESH_Unique_ID "C059030"
FAM_000411  PRD_000005   42 1 ChemSpider SMILE
;
O=C3N(C)C8(C(=O)OCC(NC(=O)c1nc2c(cc1O)cccc2)C(=O)NC(C(=O)N(C)C4C(=O)N(C)C7(C(=O)OCC(C(=O)NC(C(=O)N(C)C3C(SC(C)CC)SC4)C)NC(=O)c5nc6c(cc5O)cccc6)CC7C)C)CC8C
;
FAM_000411  PRD_000005   43 1 ChembankID External_Reference_ID 907311


#
loop_
_pdbx_reference_entity_details.family_prd_id
_pdbx_reference_entity_details.ordinal
_pdbx_reference_entity_details.source
_pdbx_reference_entity_details.text
FAM_000411 1 "PMID:7918461"
; Triostin A, a naturally occurring quinoxaline antibiotic that contains
 N-methyl groups on the valine and cysteine residues, binds sequence
 specifically to DNA at NCGN sites. [N-MeCys3,N-MeCys7]-TANDEM
 (CysMeTANDEM), a synthetic quinoxaline antibiotic, differs in its
 chemical structure from triostin A only at the valine residues, which
 contain no N-methyl substituents. CysMeTANDEM has a sequence
 specificity different from triostin A, binding specifically to DNA at
 NTAN sites. Triostin A binds to [d(GACGTC)]2 as a bis-intercalator
 around the CpG step, and the peptide ring of the drug binds in the
 minor groove of the DNA. The central C.G base pairs of the complex are
 underwound with an average helical twist angle of approximately -9.0
 degrees and buckle inward by about 25 degrees. There are
 intermolecular hydrogen bonds between each of the Ala NH and the GN3
 protons of the CpG binding site. Similar structural features are
 observed in the solution structure of the CysMeTANDEM-[d(GATATC)]2
 complex. However, in the structure of the triostin A-[d(GACGTC)]2
 complex, two intermolecular hydrogen bonds between each of the Ala CO
 oxygens of the drug and the 2-amino protons of guanine are
 observed. These hydrogen bonds do not form in the CysMeTANDEM-DNA
 complex. Instead, CysMeTANDEM contains two intramolecular hydrogen
 bonds between the Ala CO atoms and the Val amide protons, making the
 Ala CO atoms unavailable to form two intermolecular hydrogen
 bonds. 
;
FAM_000411 2 "PMID:7918462"
; CysMeTANDEM binds sequence specifically to CpI steps as
 well as TpA steps as a bis-intercalator with the peptide backbone in
 the minor groove of the DNA. Only nonspecific, nonintercalative
 binding is observed between triostin A and DNA containing a CpI
 step. Comparison of the CysMeTANDEM-[d(GGACITCC)]2 complex to the
 CysMeTANDEM-[d(GGA-TATCC)]2 complex indicates that the structures of
 both complexes are very similar. However, CysMeTANDEM binds less
 tightly to [d(GGACITCC)]2 than to [d(GGATATCC)]2. The NMR evidence
 presented provides molecular insight into the role of stacking
 interactions and hydrogen bonding between the drug and the DNA in the
 sequence-specific binding of CysMeTANDEM to TpA sites and of triostin
 A to CpG sites.
;
FAM_000411 3 "DOI:10.1093/nar/gki916 1283521"
; The major structural determinant of the preference to bind to CpG
 binding sites on DNA exhibited by the natural quinoxaline
 bis-intercalators echinomycin and triostin A, or the quinoline
 echinomycin derivative, 2QN, is the 2-amino group of guanine
 (G). However, relocation of this group by means of introduction into
 the DNA molecule of the 2-aminoadenine (=2,6-diaminopurine, D) base in
 place of adenine (A) has been shown to lead to a drastic
 redistribution of binding sites, together with ultratight binding of
 2QN to the sequence DTDT. Also, the demethylated triostin analogs,
 TANDEM and CysMeTANDEM, which bind with high affinity to TpA steps in
 natural DNA, bind much less tightly to CpI steps, despite the fact
 that both adenosine and the hypoxanthine-containing nucleoside,
 inosine (I), provide the same hydrogen bonding possibilities in the
 minor groove. To study both the increased binding affinity of 2QN for
 DTDT relative to GCGC sites and the remarkable loss of binding energy
 between CysMeTANDEM and ICIC compared with ATAT, a series of
 thermodynamic integration free energy simulations involving
 conversions between DNA base pairs have been performed. Our results
 demonstrate that the electrostatic component of the stacking
 interactions between the heteroaromatic rings of these compounds and
 the bases that make up the intercalation sites plays a very important
 role in the modulation of their binding affinities.
;
FAM_000411 4 "PMID:7853395"
; The quinomycin antibiotic UK-63052 (designated QN) exhibits a chemical
 structure related to the antibiotic echinomycin which is known to
 bisintercalate into DNA. Common features among these antibiotics
 include two heterocyclic aromatic ring systems propagating from a
 cross-bridged cyclic octadepsipeptide scaffold. We report on the
 solution structure of the QN-d(A1-C2-A3-C4-G5-T6-G7-T8) complex (one
 QN molecule per duplex) based on a combined NMR-molecular dynamics
 study including intensity-based refinement. The 3-hydroxy quinaldic
 acid rings bisintercalate into the duplex at (A3-C4).(G5-T6) steps and
 stack with flanking Watson-Crick A3.T6 and C4.G5 base-pairs. The
 intercalation sites at (A3-C4).(G5-T6) steps are wedge-shaped and
 unwound, with significant unwinding also observed at the
 (C4-C5).(C4-G5) step bracketed between the intercalation sites. The
 cross-bridged cyclic octadepsipeptide is positioned in the minor
 groove with the methyl groups on its Ala and NMe-MCp residues directed
 towards and making van der Waals contacts with the minor groove edge
 of the duplex. A pair of adjacent intermolecular hydrogen bonds
 between the Ala backbone atoms and the G5 minor groove edge (Ala-NH to
 G5-N(3) and G5-NH2e to Ala-CO) account for the sequence specificity
 associated with complex formation. 
;
FAM_000411 5 "PMID:1310611"
; Imino proton exchange studies have been reported on the complexes
 formed by bisintercalation of luzopeptin around the two central A.T
 pairs of the d(CCCATGGG) and d(AGCATGCT) duplexes and of echinomycin
 around the two central C.G pairs of the d(AAACGTTT) and
 d(CCAAACGTTTGG) duplexes. The depsipeptide backbone of the drugs
 occupies the minor groove of the complexes at the bisintercalation
 site. For the two base pairs sandwiched between the aromatic rings of
 the drug, the base-pair lifetime is strongly increased, and the
 dissociation constant is correspondingly reduced. Hence, the lifetime
 of the open state is unchanged. This suggests similar open states in
 the free duplex and in the complex. In contrast to the sandwiched base
 pairs, the base pairs flanking the intercalation site are not
 stabilized in the complex. Thus, the action of the bisintercalating
 drug may be compared to a vise clamping the inner base pairs. Analysis
 suggests that base-pair opening may require prior unwinding or bending
 of the DNA duplex.
;
FAM_000411 6 "PMID:8448108"
; The three-dimensional structure of a complex of CysMeTANDEM and the
 DNA hexamer [d(GATATC)]2 using two-dimensional 1H NMR derived NOE and
 dihedral bond angle constraints was determined. This is the first
 structure of a TpA-specific quinoxaline antibiotic in complex with
 DNA. CysMeTANDEM binds to and affects the structure of the DNA in a
 manner similar to that observed in complexes of the CpG-specific
 quinoxaline antibiotics triostin A and echinomycin with DNA The two
 quinoxaline rings bisintercalate on either side of the two central T.A
 base pairs and the peptide ring lies in the minor groove. The central
 A.T base pairs of the complex are underwound (average helical twist
 angle of approximately -10 degrees) and buckle inward by approximately
 20 degrees. There are intermolecular hydrogen bonds between each of
 the Ala NH and the AN3 protons of the TpA binding site, analogous to
 those observed between Ala NH and GN3 in the crystal structures of the
 CpG-specific complexes of echinomycin and triostin A with
 DNA. However, the structure of the peptide ring of CysMeTANDEM in the
 complex differs from that of echinomycin and triostin A.
;
FAM_000411 7 "PMID:31902"
; An ethidium homodimer and an acridine ethidium heterodimer have been
 synthesized. The ethidium and the acridine chromophore were introduced
 in such bifunctional intercalators in order to allow the fluorometric
 study of the interaction of such molecules with DNA. Conformational
 studies of these molecules by visible absorption and NMR spectroscopy
 indicate that these dimers exist in equilibrium between folded and
 unfolded conformations and that this equilibrium is pH and temperature
 dependent.
;
FAM_000411 8 "PMID:7708489"
; One and two dimensional 1H NMR spectroscopy has been used to
 characterize the binding of a homodimeric thiazole orange dye,
 1,1'-(4,4,8,8-tetramethyl-4,8-diaza-undecamethylene)-bis-4-
 (3-methyl-2,3-dihydro-(benzo-1,3-thiazole)-2-methylidene)-quinolin ium
 tetraiodide (TOTO), to various double stranded DNA
 oligonucleotides. TOTO binds strongly to all the oligonucleotides
 used, but usually more than one complex is observed and exchange
 between different binding sites broadens the lines in the NMR
 spectra. Complete precipitation occurs when TOTO is bound to small
 oligonucleotides. Binding to larger oligonucleotides occurs by
 bis-intercalation. The 1:1 complex of TOTO with the oligonucleotide
 d(CCGACTGATGC):d (GCATCAGTCGG) gave only one complex that was shown to
 be a bis-intercalation in the CTGA:TCAG binding site. The binding to
 this site was also characterized by studying the TOTO complex with the
 d(CCGCTGAGC):d(GCTCAGCGG) oligonucleotide. NOE connectivities and
 molecular modelling were used to characterize the complex. The 1:1
 complex of TOTO with the oligonucleotide d(CCGCTAGCG):d(CGCTAGCGG)
 containing a CTAG:CTAG binding site was similarly characterized by
 NMR. It was concluded that the binding of TOTO to larger
 oligonucleotides is site selective with CTAG:CTAG as the preferred
 binding site.
;
FAM_000411 9 "PMID:8797854"
; LU 79553, a bis-naphthalimide drug highly active against human solid
 tumour xenografts, has been shown to bis-intercalate into DNA with a
 helix-unwinding angle of 37 degrees. Footprinting experiments with
 DNase I reveal that the drug is selective for mixed nucleotide
 sequences characterised by an alternating purine-pyrimidine motif,
 particularly those containing GpT (ApC) and TpG (CpA) steps. Derivatives 
 bearing nitro or amino substituents on the naphthalimide chromophores 
 bind at essentially identical sites. The footprinting profiles on tyrT DNA 
 and on two fragments from pBS bear a remarkable resemblance to those 
 determined for nogalamycin, an antibiotic which binds intercalatively 
 leaving bulky carbohydrate substituents blocking both the major and 
 minor grooves of the helix. Several lines of evidence indicate that the 
 bis-naphthalimides recognise their preferred binding sites via the unusual 
 expedient of intercalating from the major groove. Footprints on the complementary
 DNA strands sometimes appear staggered in the 5'direction. 
 Repositioning the 2-amino group of G.C base pairs, which
 serves as a critical minor-groove marker, by substitution with inosine
 and/or 2,6-diaminopurine has little effect on the distribution of
 binding sites for LU 79553. The bis-naphthalimides affect the
 guanine-specific reaction with dimethyl sulfate (which reacts with the
 N7 position of the base located in the major groove) but not reactions
 with tetrachloropalladinate or methylene blue. Photoactivation of LU
 79553-DNA complexes leads to a small amount of strand scission mainly
 at guanine residues. These observations make a strong case for binding
 via the major groove of the double helix, in contrast to nearly all
 common intercalating drugs, which could be important in explaining the
 unique biological selectivity of bis-naphthalimides.
;
FAM_000411 10 "DOI:10.1016/j.phrs.2004.01.005"
; Echinomycin, in typical DNA minor groove binder, had comparable
 efficacy compared to 5-FU in the phase II trail of colon cancer
 treatment. To improve echinomycin's drawback (hydrophobicity,
 toxicity), the YK-2000 series were synthesized (echinomycin
 analogues). Among these, YK-2000 had the best in vitro cytotoxicity on
 six different human solid cancer cell lines. Echinomycin and YK-2000
 were enabled to induce the apoptosis on the HT-29 colorectal cancer
 cell line. The hypothesis that apoptosis in the HT-29 cell was
 triggered by echinomycin and YK-2000 were supported through DNA
 laddering, poly-(ADP-ribose) polymerase (PARP) cleavage, and flow
 cytometric analysis. In order to explore the signaling pathway of
 echinomycin and YK-2000, we examined the phosphorylation of
 extracellular signal-regulated kinase1/2 (ERK1/2), stress-activated
 protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 MAP
 kinase. However, what the mechanism of cancer cell death would be
 induced by echinomycin and YK-2000 is unknown.
;
FAM_000411 11 "PMID:18071270"
; The relative and absolute configuration of antitumor cyclic
 depsipeptide SW-163s have been determined. The SW-163 homologs D, F
 and G were isolated and identified as known compounds UK-63598,
 UK-65662 and UK-63052, respectively. Both enantiomers of the unusual
 constitutive amino acid, N-methylnorcoromic acid, were synthesized in
 chiral forms starting from (R)- and (S)-1,2-propanediol. The
 hydrolyzate of SW-163D, a major constituent of this family, was
 converted with Marfey's reagent,
 1-fluoro-2,4-dinitrophenyl-5-L-alanine-amide (L-FDAA), and the
 resulting mixture of amino acid derivatives was subjected to an LC/MS
 analysis. Compared with authentic samples, the analytical data
 unambiguously show that SW-163D consisted of L-Ala, D-Ser and (1S,
 2S)-N-methylnorcoronamic acid. The remaining stereochemistry of the
 N-methylcysteine moieties was determined from NOE data.
;
FAM_000411 12 "PMID:7818504"
; The quinoxaline antibiotics (triostins and quinomycins) are cyclic
 octadepsipeptides, produced by various strains of Streptomycetes,
 which owe their antitumour and antibiotic activities to their ability
 to act as potent inhibitors of DNA transcription. Quinoxaline
 chromophores, attached at opposite ends of the peptide structure,
 allow the antibiotic to adopt a staple-like conformation suitable for
 bifunctional intercalation. Footprinting studies have shown that all
 natural derivatives bind best to the CpG dinucleotide. Several novel
 structural features have been reported for a new family of quinomycin
 antibiotics (UK- 65,662) that contain 3-hydroxyquinoline chromophores
 (in place of the quinoxaline rings of echinomycin) and unusual
 methylcyclopropyl residues instead of the valine residues. In the
 past, a number of synthetic quinomycins bearing modified chromophores
 have been shown to exhibit subtly different DNAbinding affinities,
 including increased affinity for poly(dA *dT), although similar
 selectivities for CpG sites. The antibiotic UK- 63,052 (differing from
 UK-65,662 only in the nature of the alkyl group on the thioacetal
 cross-bridge) has recently been studied using footprinting methods
 that indicate strong reversible binding to DNA. UK-63,052 increases
 the mobility of kinetoplast DNA, whereas echinomycin does not, an
 observation interpreted as tight binding of the former under
 conditions in which the echinomycin-DNA complex dissociates. Not all
 CpG sites appear to represent good binding sites; UK-63,052 appears to
 be more sensitive to the nature of the flanking base pairs than
 echinomycin. CpG sites surrounded by A-T base pairs were found to be
 the most favoured, although binding to other CpG sites was not
 excluded. Discrimination against sites to which echinomycin bound less
 well [such as 5'-GCG (5'-CGC)] appeared to be more exaggerated for
 UK-63,052, while different sensitivities to modification of adenine
 bases by diethylpyrocarbonate have been reported. Several proposals
 for the modified sequence selectivity of UK-63,052 have been
 presented; the most likely origin of these differences is concluded to
 lie in the hydroxy substituent in the 3-position on the quinoline ring
 which, through altering the charge distribution on the chromophores,
 seems likely to affect (enhance) stacking interactions with the
 adjacent base pairs. Several crystal structures have illustrated
 molecular details of the interaction of echinomycin and triostin with
 DNA duplexes. The most notable feature of these complexes is a
 radical druginduced change in DNA conformation in which the A-T base
 pairs flanking the drug-binding site adopt the Hoogsteen pairing
 scheme in which the purine base flips into a syn glycosidic
 conformation. Subsequently, much interest in the quinoxaline
 antibiotics has focused on the role of Hoogsteen base pairing in
 stabilizing the drug-DNA complex in solution.
;
FAM_000411 13 "PMID:17268609"
; Echinomycin is the prototypical bisintercalator, a molecule that binds
 to DNA by inserting two planar chromophores between the base-pairs of
 duplex DNA, placing its cyclic depsipeptide backbone in the minor
 groove. As such, it has been the focus of an extensive number of
 investigations into its biological activity, nucleic acid binding and,
 to some extent, its structure-activity relationships. However,
 echinomycin is also the parent member of an extended family of natural
 products that interact with DNA by a similar mechanism of
 bisintercalation. The structural variety in these compounds leads to
 changes in sequence selectivity and and biological activity,
 particularly as anti-tumour and anti-viral agents. One of the more
 recently identified marine natural products that is moving close to
 clinical development is thiocoraline, and it therefore seems timely to
 review the various bisintercalator natural products.
;
FAM_000411 14 "PMID:11097063"
; The luzopeptin antibiotics contain a cyclic decadepsipeptide to which
 are attached two quinoline chromophores that bisintercalate into
 DNA. Although they bind DNA less tightly than the structurally related
 quinoxaline antibiotics echinomycin and triostin A, the molecular
 basis of their interaction remains unclear. We have used the PCR in
 conjunction with novel nucleotides to create specifically modified DNA
 for footprinting experiments. In order to study the influence that
 removal, addition or relocation of the guanine 2-amino group, which
 normally identifies G.C base pairs from the minor groove, has on the
 interaction of luzopeptin antibiotics with DNA. The presence of a
 purine 2-amino group is not strictly required for binding of
 luzopeptin to DNA, but the exact location of this group can alter the
 position of preferred drug binding sites. It is, however, not the sole
 determinant of nucleotide sequence recognition in luzopeptin-DNA
 interaction. Nor can the selectivity of luzopeptin be attributed to
 the quinoline chromophores, suggesting that an analogue mode of DNA
 recognition may be operative. This is in contrast to the digital
 readout that seems to predominate with the quinoxaline antibiotics.
;
FAM_000411 15 "PMID:4000957"
; Two members of the quinoxaline antibiotic family, echinomycin and
 triostin A, form crystals complexed to a DNA fragment with the
 sequence d(CpGpTpApCpG). The crystal structure of both complexes was
 solved by X-ray diffraction to near-atomic resolution. The two
 structures are similar to each other with differences in some details
 due to the shorter cross bridge of echinomycin. Both molecules act as
 bis intercalators surrounding the d(CpG) sequence at either end of the
 double helix. Alanine forms sequence-specific hydrogen bonds to
 guanines in the minor groove. The two central AT base pairs are held
 together by Hoogsteen base pairing with adenine in the syn
 conformation in both complexes. An octahedrally hydrated magnesium ion
 is found in the crystal lattice that plays an important role in
 organizing the lattice as well as stabilizing the complex by hydrogen
 bonding both to base pairs of DNA and to the quinoxaline ring nitrogen
 atoms in the major groove side of the DNA double helix. A functional
 description of the various amino acids in quinoxaline antibiotics is
 given, together with possible modifications that might affect
 biological activity.
;
FAM_000411 16 "PMCID:PMC1185755"
; Quinomycin C, triostin A and triostin C are peptide antibiotics of
 the quinoxaline family, of which echinomycin (quinomycin A) is also a
 member. They all remove and reverse the supercoiling of closed
 circular duplex DNA from bacteriophage PM2 in the fashion
 characteristic of intercalating drugs
;
FAM_000411 17 "PMID:PMC1163915"
; Echinomycin (NSC-13502, Quiniomycin A), a small-molecule known to bind
 DNA in a sequence-specific fashion. The molecule is a cyclic
 depsipeptide metabolite. It has broad activity against bacteria, fungi
 and viruses and has found application as an antitumor agent and acts
 by bifunctional intercalation of nucleic acids. Recent research has
 shown quinomycin A to be an extremely potent inhibitor of
 Hypoxia-inducible factor-1 (HIF-1). This transcription factor plays an
 essential role in tumor progression and metastasis.
 Echinomycin intercalates into DNA at two locations simultaneously in a
 sequence-specific fashion, thereby inhibiting DNA replication and RNA
 synthesis Has antitumour and antibacterial activity. Antitumor
 antibiotic. Powerful, selective inhibitor of nucleic acid synthesis in
 vitro.
;
FAM_000411 18 "PMID:2175303"
; UK63052, a novel derivative of the quinomycin group of bifunctional
 intercalating antibiotics containing uinaldic acid substituted
 quinomycins with unusual bridgehead sulfur substitution Binds strongly
 but reversibly to DNA and decreases the gel mobility of most DNA
 fragments. The drug binds selectively to the dinucleotide CpG though
 not all such sequences present good binding sites. Binding is best
 when CG is surrounded by AT base pairs. UK63052 and echinomycin have
 different effects on DNA structure as assessed by changes in the
 sensitivity to modification by diethylpyrocarbonate.
 Displays both antimicrobial and antitumor properties.
;


#
loop_
_citation.id
_citation.year
_citation.journal_volume
_citation.page_first
_citation.page_last
_citation.pdbx_database_id_DOI
_citation.pdbx_database_id_PubMed
_citation.title
_citation.journal_abbrev
  1 2005 33 6214 6224 10.1093/nar/gki916 1283521
; Role of stacking interactions in the binding sequence preferences of
 DNA bis-intercalators: insight from thermodynamic integration free
 energy simulations
;
"Nucleic Acids Res."
  2 1994 22 5484 5491 ? 7816641
; NMR investigation of Hoogsteen base pairing in quinoxaline 
 antibiotic-DNA complexes: comparison of 2:1 echinomycin, 
 triostin A and [N-MeCys3,N-MeCys7] TANDEM complexes with 
 DNA oligonucleotides
;
"Nucleic Acids Research"
  3 1993 32 2498 2508 10.1021/bi00061a006 ?
; Solution structure of a complex between 
 [N-MeCys3,N-MeCys7]TANDEM and [d(GATATC)]2
;
Biochemistry
  4 1994 18 12397 12404 ? 7918462
; Sequence specificity of quinoxaline antibiotics. 2. NMR studies of the
 binding of [N-MeCys3,N-MeCys7]TANDEM and triostin A to DNA containing
 a CpI step
;
Biochemistry
  5 1994 18 12386 12396 ? 7918461
; Sequence specificity of quinoxaline antibiotics. 1. Solution structure
 of a 1:1 complex between triostin A and [d(GACGTC)]2 and comparison
 with the solution structure of the
 [N-MeCys3,N-MeCys7]TANDEM-[d(GATATC)]2 complex.
;
Biochemistry
  6 1995 236 164 179 ? 7853395
"Solution structure of a quinomycin bisintercalator-DNA complex"
"J Mol Biol."
  7 2005 33 5622 5632 10.1093/nar/gki869 ?
; Characterization of the bisintercalative DNA binding mode of a
 bifunctional platinum/acridine agent
;
"Nucleic Acids Research"
  8 1993 32 2498 2508 ? 8448108
; Solution structure of a complex between [N-MeCys3,N-MeCys7]TANDEM and
 [d(GATATC)]2.
;
"Biochemistry"
  9 1992 31 1407 1415 ? 1310611
; Proton exchange in DNA-luzopeptin and DNA-echinomycin bisintercalation
 complexes: rates and processes of base-pair opening
;
Biochemistry
  10 1978 17 5071 5078 ? 31902
; DNA bifunctional intercalators. I. Synthesis and conformational
 properties of an ethidium homodimer and of an acridine ethidium
 heterodimer
;
Biochemistry
  11 1995 23 753 760 ? 7708489
; Site selective bis-intercalation of a homodimeric thiazole orange dye
 in DNA oligonucleotides
;
"Nucleic Acids Research"
  12 1996 240 195 208 ? 8797854
; Sequence-selective intercalation of antitumour bis-naphthalimides into
 DNA. Evidence for an approach via the major groove.
;
"Eur J Biochem."
  13 2004 50 201 207 10.1016/j.phrs.2004.01.005 ?
; Echinomycin and a novel analogue induce apoptosis of HT-29 cells via
 the activation of MAP kinases pathway
;
"Pharmacological Research"
  14 2007 71 2969 2976 ? 18071270 
"Relative and Absolute Configuration of Antitumor Agent SW-163D"
"Biosci Biotechnol Biochem."
  15 1994 304 967 979 ? 7818504
; Binding of quinomycin antibiotic UK-65,662 to DNA: 'H-n.m.r. studies of
 drug-induced changes in DNA conformation in complexes with d(ACGT)2
 and d(GACGTC)2
;
"Biochem. J."
  16 2008 47 7900 7906 10.1021/bi800573p ? 
"DNA Binding by Analogues of the Bifunctional Intercalator TANDEM"
Biochemistry
  17 2007 24 109 126 ? 17268609
; Bisintercalator natural products with potential therapeutic
 applications: isolation, structure determination, synthetic and
 biological studies
;
"Nat Prod Rep."
  18 2005 33 6214 6224 ? 16282585
; Role of stacking interactions in the binding sequence preferences of
 DNA bis-intercalators: insight from thermodynamic integration free
 energy simulations.
;
"Nucleic Acids Res."
  19 2000 19 1337 1353 ? 11097063 
; DNA recognition by quinoline antibiotics: use of base-modified DNA
 molecules to investigate determinants of sequence-specific binding of
 luzopeptin
;
"Nucleosides Nucleotides Nucleic Acids"
  20 1986 6 275 340 ? 3526052 
"Polyfunctional DNA intercalating agents"
"Med Res Rev."
  21 1982 14 805 809 ? 6182040
"Nilemycin, an intercalating agent for deoxyribonucleic acid"
"Int J Biochem."
  22 1994 7 109 122 ? 7826671
"DNA recognition by intercalators and hybrid molecules"
"J Mol Recognit."
  23 1999 6 1 27 ? 9873113 
"Pyrroloquinoline and pyridoacridine alkaloids from marine sources"
"Curr Med Chem."
  24 1985 13 2305 2323 ? 4000957
; A comparison of the structure of echinomycin 
 and triostin A complexed to a DNA fragment
;
"Nucleic Acids Res."
  25 1984 225 1115 1121 ? 6474168 
"The molecular structure of a DNA-triostin A complex"
Science
  26 1986 4 319 342 ? 3271447
; Interactions of quinoxaline antibiotic and DNA: 
 the molecular structure of a triostin A-d(GCGTACGC) complex
;
"J Biomol Struct Dyn."
  27 1986 232 1255 1258 ? 3704650 
"Non-Watson-Crick G.C and A.T base pairs in a DNA-antibiotic complex."
Science
  28 2006 2 423 428 doi:10.1038/nchembio803 ?
"Total biosynthesis of antitumor nonribosomal peptides in Escherichia coli"
"Nature Chemical Biology"
  29 1984 ? 1601 1605 10.1039/P29840001601 ?
"Crystal and molecular structure of the DNA-binding antitumour antibiotic triostin A"
"J. Chem. Soc., Perkin Trans. 2"
  30 1995 51 987 999 10.1107/S010876819401503X ? 
"Structures of quinoxaline antibiotics"
"Acta Crystallogr.,Sect.B:Struct.Sci."
 31 1982 104 3401 3408 10.1021/ja00376a027 ?
; Crystal and molecular structure of the quinoxaline antibiotic 
  analog TANDEM (des-N-tetramethyltriostin A)
;
"J. Am. Chem. Soc."
  32  1981 289 817 819 10.1038/289817a0 ?
"Structure of TANDEM and its implication for bifunctional intercalation into DNA"
Nature
  33 2005 65 9047 9055 ? 16204079
"Echinomycin, a Small-Molecule Inhibitor of Hypoxia-Inducible Factor-1 DNA-Binding Activity"
"Cancer Research"
  34 2007 104 9445 9450 10.1073/pnas.0611662104  ?
"Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy"
"Proc. Nat. Acad. Sci."
  35 2005 D61 442 448 10.1107/S090744490500137X  ?
"Structures of complexes between echinomycin and duplex DNA"
"Acta Crystallogr.,Sect.D:Biological Crystallography"
  36 1995 246 164 179 ? 7853395 
"Solution Structure of a Quinomycin Bisintercalator-DNA Complex"
"Journal of Molecular Biology"
  37 1981 ? 46 47 10.1039/C39810000046 ? 
"Characterisation of eight antibiotics of the quinomycin group by field desorption mass spectrometry"
"J. Chem. Soc., Chem. Commun."
  38 1990 43 796 808 ? 2387774
"Quinaldopeptin, a novel antibiotic of the quinomycin family"
"J Antibiot (Tokyo)"
  39 2004 50 201 207 ? 15177310
"Echinomycin and a novel analogue induce apoptosis of HT-29 cells via the activation of MAP kinases pathway"
"Pharmacol. Res."
  40 1995 51 987 999 10.1107/S010876819401503X  ? 
"Structures of quinoxaline antibiotics"
"Acta Crystallogr.,Sect.B:Struct.Sci."
  41 1989 42 206 217 ? 2925512
; UK-63,052 complex, new quinomycin antibiotics from Streptomyces
 braegensis subsp. japonicus; taxonomy, fermentation, isolation,
 characterisation and antimicrobial activity.
;
"J Antibiot (Tokyo)."


#
loop_
_citation_author.citation_id
_citation_author.ordinal
_citation_author.name
  1 1 "Marco, E."
  1 2 "Negri, A."
  1 3 "Luque, F.J."
  1 4 "Gago, F."
  3 1 "Addess, K.J."
  3 2 "Feigon, J."
  4 1 "Addess, K.J."
  4 2 "Feigon, J."
  5 1 "Addess, K.J."
  5 2 "Feigon, J."
  6 1 "Chen, H."
  6 2 "Patel, D.J."
  7 1 "Choudhury, J.R."
  7 2 "Bierbach, U."
  8 1 "Addess, K.J."
  8 2 "Sinsheimer, J.S."
  8 3 "Feigon, J."
  9 1 "Leroy, J.L."
  9 2 "Gao, X.L."
  9 3 "Misra, V."
  9 4 "Gueron, M."
  9 5 "Patel, D.J."
  10 1 "Gaugain, B."
  10 2 "Barbet, J."
  10 3 "Oberlin, R."
  10 4 "Roques, B.P."
  10 5 "Le Pecq, J.B."
  11 1 "Jacobsen, J.P."
  11 2 "Pedersen, J.B."
  11 3 "Hansen, L.F."
  11 4 "Wemmer, D.E."
  12 1 "Bailly, C."
  12 2 "Brana, M."
  12 3 "Waring. M.J."
  13 1 "Park, J.Y." 
  13 2 "Park, S.J."
  13 3 "Shim, K.Y."
  13 4 "Lee, K.J."
  13 5 "Kim, Y.-B."
  13 6 "Kim, Y.H."
  13 7 "Kim, S.K."
  14 1 "Nakaya, M." 
  14 2 "Oguri, H." 
  14 3 "Takahashi, K." 
  14 4 "Fukushi, E." 
  14 5 "Watanabe, K." 
  14 6 "Oikawa, H."
  15 1 "Searle, M.S."
  16 1 "Hampshire, A.J."
  16 2 "Rusling, D.A."
  16 3 "Bryan, S."
  16 4 "Paumier, D."
  16 5 "Dawson, S.J."
  16 6 "Malkinson, J.P."
  16 7 "Searcey , M."
  16 8 "Fox, K.R."
  17 1 "Dawson, S." 
  17 2 "Malkinson, J.P." 
  17 3 "Paumier, D." 
  17 4 "Searcey, M."
  18 1 "Marco, E."
  18 2 "Negri, A." 
  18 3 "Luque, F.J." 
  18 4 "Gago, F."
  19 1 "Bailly, C." 
  19 2 "Crow, S." 
  19 3 "Minnock, A." 
  19 4 "Waring, M.J."
  20 1 "Wakelin, L.P."
  21 1 "Shimi, I.R."
  21 2 "Abdallah, N.M."
  21 3 "Ali, F.T."
  21 4 "Khater, H.D."
  22 1 "Waring, M.J." 
  22 2 "Bailly, C."
  23 1 "Ding, Q."
  23 2 "Chichak, K." 
  23 3 "Lown, J.W."
  24 1 "Ughetto, G." 
  24 2 "Wang, A.H." 
  24 3 "Quigley, G.J." 
  24 4 "van der Marel, G.A." 
  24 5 "van Boom, J.H." 
  24 6 "Rich, A."
  25 1 "Wang, A.H." 
  25 2 "Ughetto, G."
  25 3 "Quigley, G.J."
  25 4 "Hakoshima, T." 
  25 5 "van der Marel, G.A."
  25 6 "van Boom, J.H."
  25 7 "Rich, A."
  26 1 "Wang, A.H."
  26 2 "Ughetto, G."
  26 3 "Quigley, G.J."
  26 4 "Rich, A."
  27 1 "Quigley, G.J."
  27 2 "Ughetto, G."
  27 3 "van der Marel, G.A."
  27 4 "van Boom J.H."
  27 5 "Wang, A.H."
  27 6 "Rich, A."
  28 1 "Watanabe, K."
  28 2 "Hotta, K."
  28 3 "Praseuth, A.P."
  28 4 "Koketsu, K."
  28 5 "Migita, A."
  28 6 "Boddy, C.N."
  28 7 "Wang, C.C.C."
  28 8 "Oguri, H."
  28 9 "Oikawa, H."
  29 1 "Sheldrick, G.M."
  29 2 "Guy, J.J."
  29 3 "Kennard, O."
  29 4 "Rivera, V."
  29 5 "Waring, M.J."
  30 1 "Sheldrick, G.M."
  30 2 "Heine, A."
  30 3 "Schmidt-Base, K."
  30 4 "Pohl, E."
  30 5 "Jones, P.G."
  30 6 "Paulus, E."
  30 7 "Waring, M.J."
  31 1 "Hossain, M.B."
  31 2 "van der Helm, D."
  31 3 "Olsen, R.K."
  31 4 "Jones, P.G."
  31 5 "Sheldrick, G.M." 
  31 6 "Egert, E."
  31 7 "Kennard, O."
  31 8 "Waring, M.J."
  31 9 "Viswamitra, M.A."
  32 1 "Viswamitra, M.A."
  32 2 "Kennard, O."
  32 3 "Cruse, W.B.T." 
  32 4 "Egert, E."
  32 5 "Sheldrick, G.M." 
  32 6 "Jones, P.G."
  32 7 "Waring, M.J."
  32 8 "Wakelin, L.P.G."
  32 9 "Olsen, R.K."
  33 1 "Kong, D."
  33 2 "Park, E.J."
  33 3 "Stephen, A.G."
  33 4 "Calvani, M."
  33 5 "Cardellina, J.H."
  33 6 "Monks, A."
  33 7 "Fisher, R.J."
  33 8 "Shoemaker, R.H."
  33 9 "Melillo, G."
  34 1 "Cairns, R.A."
  35 1 "Cuesta-Seijo, J.A."
  35 2 "Sheldrick, G.M." 
  36 1 "Chen, H."
  36 2 "Patel, D.J." 
  37 1 "Bojesen, G."
  37 2 "Gauvreau, D."
  37 3 "Williams, D.H."
  37 4 "Waring, M.J." 
  38 1 "Toda, S."
  38 2 "Sugawara, K."
  38 3 "Nishiyama, Y."
  38 4 "Ohbayashi, M."
  38 5 "Ohkusa, N."
  38 6 "Yamamoto, H."
  38 7 "Konishi, M."
  38 8 "Oki, T."
  39 1 "Park, J.Y."
  39 2 "Park, S.J."
  39 3 "Shim, K.Y."
  39 4 "Lee, K.J."
  39 5 "Kim, Y.B."
  39 6 "Kim, Y.H."
  39 7 "Kim, S.K."
  40 1 "Sheldrick, G.M."
  40 2 "Heine, A."
  40 3 "Schmidt-Base, K."
  40 4 "Pohl, E."
  40 5 "Jones, P.G."
  40 6 "Paulus, E."
  40 7 "Waring, M.J."
  41 1 "Rance, M.J."
  41 2 "Ruddock, J.C."
  41 3 "Pacey, M.S."
  41 4 "Cullen, W.P."
  41 5 "Huang, L.H."
  41 6 "Jefferson, M.T."
  41 7 "Whipple, E.B."
  41 8 "Maeda, H."
  41 9 "Tone, J."

#--------------------------------------
